483 related articles for article (PubMed ID: 28081641)
41. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
42. Antiangiogenic therapy for the treatment of pediatric solid malignancies.
Davidoff AM; Kandel JJ
Semin Pediatr Surg; 2004 Feb; 13(1):53-60. PubMed ID: 14765371
[TBL] [Abstract][Full Text] [Related]
43. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
44. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
45. Aflibercept a new target therapy in cancer treatment: a review.
Ricci V; Ronzoni M; Fabozzi T
Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
[TBL] [Abstract][Full Text] [Related]
46. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
47. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.
Arjaans M; Schröder CP; Oosting SF; Dafni U; Kleibeuker JE; de Vries EG
Oncotarget; 2016 Apr; 7(16):21247-58. PubMed ID: 26789111
[TBL] [Abstract][Full Text] [Related]
48. Vascular-immuno-phenotypic (VIP) model for locally advanced and oligo-metastatic cancer: A hypothesis.
Swamy K
Med Hypotheses; 2021 Jul; 152():110618. PubMed ID: 34102599
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
Jain RK
Cancer Cell; 2014 Nov; 26(5):605-22. PubMed ID: 25517747
[TBL] [Abstract][Full Text] [Related]
50. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.
Shi S; Chen L; Huang G
Med Oncol; 2013 Dec; 30(4):698. PubMed ID: 23982676
[TBL] [Abstract][Full Text] [Related]
52. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
Peng F; Chen M
Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317
[TBL] [Abstract][Full Text] [Related]
53. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
54. Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.
Uldry E; Faes S; Demartines N; Dormond O
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28665313
[TBL] [Abstract][Full Text] [Related]
55. [Immune therapy and tumor angiogenesis].
Takakura N
Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547
[TBL] [Abstract][Full Text] [Related]
56. Antiangiogenic therapy and tumor progression.
Blagosklonny MV
Cancer Cell; 2004 Jan; 5(1):13-7. PubMed ID: 14749122
[TBL] [Abstract][Full Text] [Related]
57. New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update.
Ghasemali S; Farajnia S; Barzegar A; Rahmati-Yamchi M; Baghban R; Rahbarnia L; Nodeh HRY
Anticancer Agents Med Chem; 2021; 21(1):3-19. PubMed ID: 32807068
[TBL] [Abstract][Full Text] [Related]
58. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents.
Zhang Q; Bindokas V; Shen J; Fan H; Hoffman RM; Xing HR
Mol Cancer Ther; 2011 Jul; 10(7):1173-84. PubMed ID: 21586628
[TBL] [Abstract][Full Text] [Related]
59. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
60. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
